Catheter Precision Announces Third VIVO Installation in France
First-ever multi-year agreement highlights commitment to French electrophysiology market
FORT MILL, S.C., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market today announces its third VIVO™ system installation in France, at the prestigious Centre Hospitalier Régional Universitaire (CHRU) Nancy. Led by Prof. Christian de Chillou, a renowned expert in ventricular tachycardia ablation, CHRU Nancy’s Clinical Electrophysiology Unit will utilize VIVO under a new multi-year agreement — a first for Catheter Precision.
CHRU Nancy is a leading tertiary referral and teaching hospital serving the Grand Est region of France. Its Electrophysiology Unit, led by Prof. Christian de Chillou, specializes in complex arrhythmia ablation and participates in European multi-center research and is recognized internationally for expertise in catheter ablation of challenging arrhythmias. Equipped with VIVO, the department will harness its non-invasive 3D mapping to optimize ventricular arrhythmia workflows, reducing procedure time and improving patient outcomes.
This follows the second VIVO deployment at CHU Rennes in July 2025, which marked Catheter Precision’s largest purchase order in Europe. CHU Rennes, performing over 150 ventricular ablations annually, demonstrated exceptional early results and physician enthusiasm. Global momentum continues with installations in France, Sweden, and the U.S., supported by CE and FDA clearances.
“Academic centers like Rennes and Nancy are pivotal for introducing VIVO early in a physician’s career, establishing long-term adoption,” said Fatih Ayoglu, European Sales Manager at Catheter Precision. “Now that a multi-year agreement has been secured with CHRU Nancy, we believe that the three most prestigious hospitals for ventricular ablation in France are using VIVO which reflects our growing momentum in France and confirms VIVO’s clinical and economic value.”
About VIVO™
Catheter Precision’s (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE Mark.
About Catheter Precision
is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that VIVO can bring. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
Investor Relations
973-691-2000
# # #
